Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of 8.10% is in line with its 5-year average of 7.84%, around the middle of its 5-year range (5.09%–12.13%).
4.02% above its 12-month average of 7.79%.
Reported quarterly profit margin; no daily interpolation.
NET PROFIT MARGIN
8.10%
NET PROFIT MARGIN AVG TTM
7.79%
NET PROFIT MARGIN AVG 3Y
8.40%
NET PROFIT MARGIN AVG 5Y
7.84%
NET PROFIT MARGIN AVG 10Y
5.72%
NET PROFIT MARGIN AVG 15Y
5.64%
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+4.02%
CURRENT VS 3Y AVG
-3.59%
CURRENT VS 5Y AVG
+3.27%
CURRENT VS 10Y AVG
+41.67%
CURRENT VS 15Y AVG
+43.68%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
8.98%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-9.80%
vs the sector median at left
IQVIA Holdings Inc.
Market Cap
$42.17B
Net Profit Margin
8.10%
TTM Avg
7.79%
3Y Avg
8.40%
5Y Avg
7.84%
Market Cap
$42.75B
Net Profit Margin
4.08%
TTM Avg
-0.87%
3Y Avg
-5.42%
5Y Avg
-7.16%
Market Cap
$40.93B
Net Profit Margin
25.03%
TTM Avg
23.70%
3Y Avg
22.66%
5Y Avg
22.55%
Market Cap
$40.81B
Net Profit Margin
19.53%
TTM Avg
19.27%
3Y Avg
18.75%
5Y Avg
17.94%
Market Cap
$49.60B
Net Profit Margin
4.52%
TTM Avg
8.06%
3Y Avg
8.30%
5Y Avg
8.27%
Market Cap
$49.88B
Net Profit Margin
15.43%
TTM Avg
47.22%
3Y Avg
37.68%
5Y Avg
33.03%
Market Cap
$33.94B
Net Profit Margin
16.82%
TTM Avg
-1.96%
3Y Avg
-34.26%
5Y Avg
-68.70%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $42.17B | 8.10% | 7.79% | 8.40% | 7.84% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.75B | 4.08% | -0.87% | -5.42% | -7.16% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $40.93B | 25.03% | 23.70% | 22.66% | 22.55% |
| Agilent Technologies, Inc. (A)vs › | $40.81B | 19.53% | 19.27% | 18.75% | 17.94% |
| Humana Inc. (HUM)vs › | $47.90B | 0.88% | 0.97% | 1.82% | 2.53% |
| Becton, Dickinson and Company (BDX)vs › | $49.60B | 4.52% | 8.06% | 8.30% | 8.27% |
| Edwards Lifesciences Corporation (EW)vs › | $49.88B | 15.43% | 47.22% | 37.68% | 33.03% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $33.94B | 16.82% | -1.96% | -34.26% | -68.70% |
| Alcon Inc. (ALC)vs › | $33.52B | 5.92% | 9.84% | 8.46% | 5.10% |
| ResMed Inc. (RMD)vs › | $31.77B | 26.94% | 27.08% | 24.30% | 22.30% |
Operating Margin
13.6%
Net Profit Margin
8.1%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 5.86% |
| 2026-03-31 | 6.60% |
| 2025-12-31 | 11.78% |
| 2025-09-30 | 8.07% |
| 2025-06-30 | 6.62% |
| 2025-03-31 | 6.50% |
| 2024-12-31 | 11.04% |
| 2024-09-30 | 7.32% |
| 2024-06-30 | 9.52% |
| 2024-03-31 | 7.71% |
| 2023-12-31 | 12.13% |
| 2023-09-30 | 8.11% |
| 2023-06-30 | 7.97% |
| 2023-03-31 | 7.91% |
| 2022-12-31 | 6.07% |
| 2022-09-30 | 7.94% |
| 2022-06-30 | 7.21% |
| 2022-03-31 | 9.11% |
| 2021-12-31 | 8.75% |
| 2021-09-30 | 7.70% |
| 2021-06-30 | 5.09% |
| 2021-03-31 | 6.22% |
| 2020-12-31 | 3.61% |
| 2020-09-30 | 3.63% |
| 2020-06-30 | -0.91% |
| 2020-03-31 | 2.98% |
| 2019-12-31 | 0.55% |
| 2019-09-30 | 2.06% |
| 2019-06-30 | 2.19% |
| 2019-03-31 | 2.16% |
| 2018-12-31 | 2.57% |
| 2018-09-30 | 2.31% |
| 2018-06-30 | 2.38% |
| 2018-03-31 | 2.69% |
| 2017-12-31 | 41.75% |
| 2017-09-30 | 3.57% |
| 2017-06-30 | 2.63% |
| 2017-03-31 | 3.14% |
| 2016-12-31 | -7.61% |
| 2016-09-30 | 6.68% |
| 2016-06-30 | 5.54% |
| 2016-03-31 | 7.18% |
| 2015-12-31 | 6.87% |
| 2015-09-30 | 7.81% |
| 2015-06-30 | 5.88% |
| 2015-03-31 | 6.41% |
| 2014-12-31 | 6.27% |
| 2014-09-30 | 6.62% |
| 2014-06-30 | 6.35% |
| 2014-03-31 | 6.90% |
| 2013-12-31 | 5.29% |
| 2013-09-30 | 5.58% |
| 2013-06-30 | 2.97% |
| 2013-03-31 | 3.93% |
| 2012-12-31 | 2.74% |
| 2012-09-30 | 4.34% |
| 2012-06-30 | 3.84% |
| 2012-03-31 | 3.74% |
